TOKYO, Japan & PARIS, France I PeptiDream Inc., a Tokyo-based pharmaceutical company (PeptiDream), and Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty driven pharmaceutical Group, today announced that they have entered into a research collaboration and license option agreement to discover, evaluate, potentially develop and launch therapeutic peptides to treat serious medical conditions in areas of therapeutic focus for Ipsen.
The research collaboration will combine PeptiDream’s proprietary peptide library with Ipsen’s expertise in peptide drug discovery and pharmaceutical R&D. The financial terms of the agreement are not disclosed. In exchange for world-wide rights to the therapeutic peptides resulting from the collaboration, Ipsen will make an upfront payment to PeptiDream and pay R&D and commercialization costs. PeptiDream will receive royalties on worldwide sales; or have the right to opt-in at predefined stages to support Japan development costs for royalty free commercial rights in that territory. In the latter circumstance, PeptiDream would also forego royalty income for ex-Japan sales.
“Our partnership with Ipsen to discover novel therapeutic peptides for serious debilitating disease reinforces the status of PeptiDream as a major force in therapeutic peptide discovery in the pharmaceutical industry worldwide,” said Patrick Reid, Ph.D., Chief Scientific Officer and Head of PeptiDream’s discovery programs.
“Ipsen and PeptiDream now enter into a research collaboration to discover novel highly-selective peptides targeting specific serious disease using the synergies of skills and competencies between both companies. We believe the Ipsen – PeptiDream agreement implements our philosophy to apply innovation for future patient care,” stated Dr. Claude Bertrand, Executive Vice president R&D, Chief Scientific Officer at Ipsen.
About Peptidream
PeptiDream Inc. is a privately-held biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS), a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit www.peptidream.com
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total turnover exceeding €1.27 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology / Dysport®, endocrinology / Somatuline® and uro-oncology / Decapeptyl®. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,900 employees. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
SOURCE: Ipsen
Post Views: 170
TOKYO, Japan & PARIS, France I PeptiDream Inc., a Tokyo-based pharmaceutical company (PeptiDream), and Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty driven pharmaceutical Group, today announced that they have entered into a research collaboration and license option agreement to discover, evaluate, potentially develop and launch therapeutic peptides to treat serious medical conditions in areas of therapeutic focus for Ipsen.
The research collaboration will combine PeptiDream’s proprietary peptide library with Ipsen’s expertise in peptide drug discovery and pharmaceutical R&D. The financial terms of the agreement are not disclosed. In exchange for world-wide rights to the therapeutic peptides resulting from the collaboration, Ipsen will make an upfront payment to PeptiDream and pay R&D and commercialization costs. PeptiDream will receive royalties on worldwide sales; or have the right to opt-in at predefined stages to support Japan development costs for royalty free commercial rights in that territory. In the latter circumstance, PeptiDream would also forego royalty income for ex-Japan sales.
“Our partnership with Ipsen to discover novel therapeutic peptides for serious debilitating disease reinforces the status of PeptiDream as a major force in therapeutic peptide discovery in the pharmaceutical industry worldwide,” said Patrick Reid, Ph.D., Chief Scientific Officer and Head of PeptiDream’s discovery programs.
“Ipsen and PeptiDream now enter into a research collaboration to discover novel highly-selective peptides targeting specific serious disease using the synergies of skills and competencies between both companies. We believe the Ipsen – PeptiDream agreement implements our philosophy to apply innovation for future patient care,” stated Dr. Claude Bertrand, Executive Vice president R&D, Chief Scientific Officer at Ipsen.
About Peptidream
PeptiDream Inc. is a privately-held biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS), a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit www.peptidream.com
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total turnover exceeding €1.27 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology / Dysport®, endocrinology / Somatuline® and uro-oncology / Decapeptyl®. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,900 employees. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
SOURCE: Ipsen
Post Views: 170
